Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
DURECT CORPORATION (DRRX) Stock Price & Overview
NASDAQ:DRRX • US2666055007
Current stock price
1.91 USD
-0.02 (-1.04%)
At close:
1.94 USD
+0.03 (+1.57%)
After Hours:
The current stock price of DRRX is 1.91 USD. Today DRRX is down by -1.04%. In the past year, price increased by 26.49%.
DRRX Key Statistics
52-Week Range0.4801 - 2.64
Current DRRX stock price positioned within its 52-week range.
1-Month Range1.86 - 1.97
Current DRRX stock price positioned within its 1-month range.
- Market Cap
- 59.306M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.10
- Dividend Yield
- N/A
DRRX Stock Performance
Today
-1.04%
1 Week
-1.55%
1 Month
N/A
3 Months
+210.57%
Longer-term
6 Months +122.09%
1 Year +26.49%
2 Years -23.29%
3 Years -66.97%
5 Years -88.83%
10 Years -90.21%
DRRX Stock Chart
DRRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DRRX. When comparing the yearly performance of all stocks, DRRX is one of the better performing stocks in the market, outperforming 96.77% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DRRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRRX. The financial health of DRRX is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DRRX Earnings
On August 12, 2025 DRRX reported an EPS of -0.07 and a revenue of 447.00K. The company beat EPS expectations (42.81% surprise) and beat revenue expectations (41.37% surprise).
Next Earnings DateNov 11, 2025
Last Earnings DateAug 12, 2025
PeriodQ2 / 2025
EPS Reported-$0.07
Revenue Reported447K
EPS Surprise 42.81%
Revenue Surprise 41.37%
DRRX Forecast & Estimates
7 analysts have analysed DRRX and the average price target is 2.55 USD. This implies a price increase of 33.51% is expected in the next year compared to the current price of 1.91.
For the next year, analysts expect an EPS growth of -105.89% and a revenue growth -92.31% for DRRX
Analysts
Analysts45.71
Price Target2.55 (33.51%)
EPS Next Y-105.89%
Revenue Next Year-92.31%
DRRX Financial Highlights
Over the last trailing twelve months DRRX reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 83.61% compared to the year before.
Income Statements
Revenue(TTM)3.12M
Net Income(TTM)-3.48M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%41.67%
Sales Q2Q%-79.41%
EPS 1Y (TTM)83.61%
Revenue 1Y (TTM)-62.89%
DRRX Ownership
Ownership
Inst Owners22.34%
Shares31.05M
Float27.26M
Ins Owners11.82%
Short Float %N/A
Short RatioN/A
DRRX Industry Overview
DRRX operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 96.3%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 41.4%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.8
- Average Debt/Equity
- 1.3
DRRX Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 910.173B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 547.212B | ||
| MRK | MERCK & CO. INC. | 11.43 | 277.022B | ||
| PFE | PFIZER INC | 8.81 | 149.775B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 118.87B | ||
| ZTS | ZOETIS INC | 16.14 | 48.007B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.541B | ||
| VTRS | VIATRIS INC | 6.03 | 17.513B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.241B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.564B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.809B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 5.47B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DRRX
Company Profile
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 13 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. The company has developed a proprietary drug product for the treatment of ADHD called Methydur.
Company Info
IPO: 2000-09-28
DURECT CORPORATION
10240 Bubb Road
Cupertino CALIFORNIA 95014 US
CEO: James E. Brown
Employees: 21
Phone: 14087771417
DURECT CORPORATION / DRRX FAQ
What does DURECT CORPORATION do?
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 13 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. The company has developed a proprietary drug product for the treatment of ADHD called Methydur.
What is the current price of DRRX stock?
The current stock price of DRRX is 1.91 USD. The price decreased by -1.04% in the last trading session.
What is the dividend status of DURECT CORPORATION?
DRRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of DRRX stock?
DRRX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of DRRX stock?
DURECT CORPORATION (DRRX) has a market capitalization of 59.31M USD. This makes DRRX a Micro Cap stock.
Can you provide the ownership details for DRRX stock?
You can find the ownership structure of DURECT CORPORATION (DRRX) on the Ownership tab.